PURPOSE OF REVIEW: Prevalence of benign prostatic hyperplasia (BPH) is increasing with the aging population worldwide. Knowledge of the natural history of BPH is crucial for primary, secondary and tertiary prevention of its progression. This review examines the evidence of the natural history of BPH, highlighting the group of patients with mild symptoms and the risk factors for progression. RECENT FINDINGS: Several community and clinical studies have demonstrated the progressive nature of BPH. Different surrogate endpoints, which include symptom score, peak urinary flow rate, prostate volume, and the occurrence of acute urinary retention and need for surgery, have been described. Prostatic specific antigen and prostate volume are the two most common predictors of clinical progression and are helpful to the clinician for identifying high-risk patients. SUMMARY: With further understanding of the natural history and the predictors of progression of BPH, management can be better tailored according to risk stratification and the results of clinical trials of effectiveness can be better interpreted.
PURPOSE OF REVIEW: Prevalence of benign prostatic hyperplasia (BPH) is increasing with the aging population worldwide. Knowledge of the natural history of BPH is crucial for primary, secondary and tertiary prevention of its progression. This review examines the evidence of the natural history of BPH, highlighting the group of patients with mild symptoms and the risk factors for progression. RECENT FINDINGS: Several community and clinical studies have demonstrated the progressive nature of BPH. Different surrogate endpoints, which include symptom score, peak urinary flow rate, prostate volume, and the occurrence of acute urinary retention and need for surgery, have been described. Prostatic specific antigen and prostate volume are the two most common predictors of clinical progression and are helpful to the clinician for identifying high-risk patients. SUMMARY: With further understanding of the natural history and the predictors of progression of BPH, management can be better tailored according to risk stratification and the results of clinical trials of effectiveness can be better interpreted.
Authors: Abdullah Barghash Alanazi; Anfal Muaddi Alshalan; Omar Ayed Alanazi; Munif Salah Alanazi; Abdulaziz Inad Alanazi; Abdullah Hussain Alanazi; Anwar Mohammed Alhadhari; Ahmed Saad Alanazi; Rahmah Abdulhadi Alanazi; Ibtisam Matan Alanazi; Mohammed Abdullah Alanazi; Mohammed Abdullah Alkhidhr; Hassan Ali Aldehneen; Raed Khalid Alanazi Journal: Electron Physician Date: 2017-09-25
Authors: Alexandre Iscaife; Gabriel Dos Anjos; Cristovão Barbosa; Willian Carlos Nahas; Miguel Srougi; Alberto Azoubel Antunes Journal: Int Braz J Urol Date: 2018 Jul-Aug Impact factor: 1.541